The Cannabinoid System as a Potential Novel Target for Alcohol‐Associated Liver Disease: A Propensity‐Matched Cohort Study

Abstract Background: Alcohol‐associated liver disease (ALD) is a leading cause of liver‐related morbidity and mortality, yet effective therapeutic options remain limited. Preclinical data suggest that modulation of the hepatic endocannabinoid system, particularly via cannabidiol (CBD), may reduce alcohol‐induced liver injury. Due to CBD’s limited clinical use, we sought to evaluate the association between cannabis use and ALD risk among patients with alcohol use disorder (AUD). Methods: Using the TriNetX US Collaborative Network, we identified adult patients with AUD between 2010